SystImmune

Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...

REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...

Redmond, Washington, USA – May 21, 2026 SystImmune, Inc. announced that multiple clinical and late-stage development data sets from...

REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...

September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...